Blueprint Medicines Corporation (BPMC): $127.85
Market Cap: $8.26 B
Deal Value: $9.1 B
France-based big pharma company Sanofi (SNY) entered a merger agreement on June 2, 2025, to acquire U.S.-based Blueprint Medicines in a deal valued at $9.1 billion, aiming to strengthen its position in rare immunology diseases.
Blueprint Medicines is a drug company that creates targeted treatments for specific types of cancer, blood diseases, and mast cell conditions—a type of white blood cell involved in allergic reactions. The company already has two approved drugs, including Ayvakit, which is used to treat systemic mastocytosis—a rare blood disease. The other drug approved by the Food and Drug Administration (FDA) is Gavreto (pralsetinib), used to treat lung and thyroid cancers.